In this article:
Tildrakizumab for Real-World Psoriasis Care: Clinical Lessons From Medically Complex and Underserved Patient Populations
Tildrakizumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds the p19 subunit of interleukin-23 (IL-23), a key cytokine in the pathogenesis of psoriasis. In the pivotal phase 3 reSURFACE 1 and 2 clinical trials, tildrakizumab demonstrated efficacy in the treatment of moderate-tosevere plaque psoriasis, with over 60% of patients achieving a 75% reduction in the Psoriasis Area and Severity Index (PASI-75) at week 12 from baseline. These findings supported tildrakizumab’s approval by the US Food and Drug Administration as a 100 mg subcutaneous injection at weeks 0, 4, and every 12 weeks thereafter.
Read more
Tildrakizumab for Real-World Psoriasis Care: Clinical Lessons From Medically Complex and Underserved Patient Populations
Tildrakizumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds the p19 subunit of interleukin-23 (IL-23), a key cytokine in the pathogenesis of psoriasis. In the pivotal phase 3 reSURFACE 1 and 2 clinical trials, tildrakizumab demonstrated efficacy in the treatment of moderate-tosevere plaque psoriasis, with over 60% of patients achieving a 75% reduction in the Psoriasis Area and Severity Index (PASI-75) at week 12 from baseline. These findings supported tildrakizumab’s approval by the US Food and Drug Administration as a 100 mg subcutaneous injection at weeks 0, 4, and every 12 weeks thereafter.
Read more
